Cargando…
Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
SIMPLE SUMMARY: Due to improved selectivity and favorable toxicity profiles, the next-generation Bruton’s tyrosine kinase inhibitors (BTKis) are replacing ibrutinib in the treatment of B-cell malignancies including chronic lymphocytic leukemia (CLL). While efficacy between different BTKi agents is p...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377923/ https://www.ncbi.nlm.nih.gov/pubmed/37509398 http://dx.doi.org/10.3390/cancers15143737 |